ABOS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Acumen Pharmaceuticals Inc (ABOS) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has promising developments in Alzheimer's treatment and positive analyst ratings, the stock's recent price performance, weak financials, and lack of strong trading signals suggest waiting for further clarity or improvement in fundamentals before investing.
The MACD histogram is negative and expanding, indicating bearish momentum. RSI is neutral at 46.132, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading below the pivot level of 2.492, with key support at 2.27 and resistance at 2.714. Overall, the technical indicators are mixed, with no clear buy signal.
Positive analyst ratings and price target increases, with BTIG raising the target to $7 and Lucid Capital initiating coverage with a $6 target.
Promising Phase 2 ALTITUDE-AD results expected in late 2026 for their Alzheimer's treatment candidate.
FDA's priority review of Biogen's LEQEMBI SubQ therapy could indirectly benefit Acumen's field.
Weak recent price performance, with a 6.64% drop in regular trading and a further 0.21% decline post-market.
Poor financial performance in Q3 2025, with net income and EPS both declining significantly.
No recent news or significant insider/hedge fund activity to drive momentum.
In Q3 2025, revenue remained at $0 with no growth. Net income dropped to -$26.45M (-11.13% YoY), and EPS fell to -0.44 (-12.00% YoY). Gross margin is 0, indicating no revenue generation. Overall, the financials are weak, with no signs of improvement.
Analysts maintain a positive outlook with Buy ratings and price targets ranging from $6 to $8. However, these targets are based on future developments, such as Phase 2 trial results in late 2026, which may not align with the user's impatience for immediate returns.
